Supplement to the Petition to the FDA to Ban Olmesartan-Containing Hypertension Medications

February 1, 2018

View as PDF.

Public Citizen submitted a supplement to its petition the Food and Drug Administration (FDA) to ban the sale of all medication containing the widely prescribed angiotensin II receptor blocker (ARB) olmesartan medoxomil because it can cause a severe gastrointestinal disorder that leads to severe and chronic diarrhea, vomiting, abdominal pain and weight loss. Since the submission of our petition, a new large cohort study was published that provides additional evidence showing that use of olmesartan is associated with a higher rate of sprue-like enteropathy compared with the use of other ARBs.

See Public Citizen’s other work on olmesartan.